Health Canada Approves Upadacitinib to Treat Adults with PsA

At week 24, minimal disease activity was attained in 25% of patients treated with 15 mg of upadacitinib and 29% of patients treated with 30 mg of upadacitinib compared with 3% of patients treated with placebo.

The most common adverse events reported with upadacitinib were increased levels of serum creatine phosphokinase, alanine transaminases and aspartate transaminases. Nasopharyngitis and upper respiratory tract infection were also reported. No new safety signals were identified.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

AbbVie. News release: Health Canada approves AbbVie’s Rinvoq (upadacitinib) for the treatment of adults with active psoriatic arthritis. 2021 Jun 7.
AbbVie. News release: Rinvoq (upadacitinib) meets primary and key secondary endpoints in phase 3 study in psoriatic arthritis. 2020 Feb 5.
AbbVie. News release: Rinvoq (upadacitinib) meets primary and all ranked secondary endpoints in phase 3 study in psoriatic arthritis. 2019 Oct 31.

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…

The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) based on a short-term study that demonstrated improved pain, function and other symptoms of nr-axSpA in patients with active disease.

In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.

References

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis

European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis

References

Related Articles